EDAP Receives the Prestigious Prix Galien for its Focal One® HIFU device
December 08 2016 - 7:30AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, today announced the award of the prestigious 2016 Prix
Galien, in the Medical Device category, for its Focal One HIFU
device dedicated to the treatment of localized prostate cancer. The
Prix Galien honors major innovative therapies or drugs introduced
to the public market and promotes significant advances in
healthcare research.
"It is a great honor to receive the prestigious Prix Galien,"
commented Marc Oczachowsky, EDAP TMS Chief Executive Officer. "This
award recognizes the therapeutic excellence of our Focal One HIFU
system as an innovative device in the treatment of localized
prostate cancer. It also rewards the outstanding work achieved by
our dedicated teams and partners in developing and bringing to
market this minimally invasive therapy preserving prostate cancer
patients’ quality of life. We are very proud to be part of the
highly selective group of companies awarded with the prestigious
Prix Galien."
The jury reviewed 120 candidates and selected nominees among six
categories. Awards were announced during the prestigious Galien
gala dinner which took place on December 7, 2016 at the Pavillon
d’Armenonville in Paris, France.
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) for prostate tissue ablation in the U.S. and for
treatment of localized prostate cancer in the rest of the world.
HIFU treatment is shown to be a minimally invasive and effective
option for prostatic tissue ablation with a low occurrence of side
effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for
surgery or who prefer an alternative option, or for patients who
failed radiotherapy treatment. Ablatherm-HIFU is approved for
commercial distribution in Europe and some other countries
including Mexico and Canada, and has received 510(k) clearance by
the U.S. FDA. The Company also markets an innovative robot-assisted
HIFU device, the Focal One®, dedicated to focal therapy of prostate
cancer. Focal One® is CE marked but is not FDA approved. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and distributes medical equipment (the Sonolith®
lithotripters’ range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
About Prix Galien
The Prix Galien was created in France in 1970 by a pharmacist
named Roland Mehl. Its aim was to promote significant advances in
pharmaceutical research. Until the creation of the Prix Galien,
this field of research had remained largely unrecognized. A
prominent jury was brought together, including clinicians,
toxicologists, pharmacologists and pharmacists. Each year, the
award has been an opportunity to give credit to the most important
drugs introduced into the public market as well as to the
achievements of the best research team in the pharmaceutical field.
Since its creation, the Galien award has grown into a major event.
It is seen as an influential event by all those interested in
pharmaceutical research, including public authorities, scientists,
pharmaceutical companies and medical press groups. For this reason,
it is also considered as the industry’s equivalent of the Nobel
prize and the highest accolade for pharmaceutical research and
development. For more information on Prix Galien, please
visit http://www.prixgalien.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management’s current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company’s filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company’s Annual Report on Form 20-F.
Contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
CG CAPITAL
877.889.1972
investorrelations@cg.capital
www.cg.capital
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Apr 2024 to May 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From May 2023 to May 2024